Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than 100 risk regions, most of the risk genes at these regions remain largely unknown.
Introduction
Prostate cancer (PrCa) affects ~1 in 7 men during their lifetime and is one of the most common cancers worldwide, with up to 58% of risk due to genetic factors 1; 2 . Genome-wide association studies (GWAS) have identified over 100 genomic regions harboring risk variants for PrCa which explain roughly one third of familial risk [3] [4] [5] [6] [7] . With few exceptions 8 , the causal variants and target susceptibility genes at most GWAS risk loci have yet to be identified. Multiple studies have shown that PrCa-and other disease-associated variants are enriched near variants that correlate with gene expression levels [9] [10] [11] [12] [13] . In fact, recent approaches have integrated expression quantitative trait loci (eQTLs) with GWAS to implicate several plausible genes for PrCa risk (e.g., IRX4, MSMB, NCOA4, NUDT11 and SLC22A3) 5; [14] [15] [16] [17] [18] [19] [20] [21] . While overlapping eQTLs and GWAS is powerful, the high prevalence of eQTLs 22 coupled with linkage disequilibrium (LD) renders it difficult to distinguish the true susceptibility gene from spurious co-localization at the same locus 23 . Therefore, disentangling LD is critical for prioritization and causal gene identification at risk loci. Gene expression imputation followed by a transcriptome-wide association study [24] [25] [26] (TWAS) has been recently proposed as a powerful approach to prioritize candidate risk genes underlying complex traits. By taking LD into account across SNPs, the resulting association statistics reflect the underlying effect of steady-state gene or alternative splicing expression levels on disease risk 25; 27 , which can be used to identify new regions or to rank genes for functional validation at known risk regions [24] [25] [26] [27] [28] . Here we perform a multi-tissue transcriptome-wide association study [24] [25] [26] to identify new risk regions and to prioritize genes at known risk regions for PrCa. Specifically, we integrate gene expression data from 48 panels measured in 45 tissues across 4, 448 individuals with GWAS of prostate cancer from the OncoArray in 142,392 men 29 . Notably, we include alternatively spliced and total gene expression data measured in tumor prostate to identify genes contributing to prostate cancer risk or to continued oncogenesis. We identify 235 gene-trait associations for PrCa with 24 (11) genes identified uniquely using models of alternative spliced (total) expression in tumor. Significant genes were found in 87 independent 1Mb regions, of which 9 regions are located more than 2Mb away from any OncoArray GWAS significant variants, thus identifying new candidate risk regions. Second, we use TWAS to investigate genes previously reported as susceptibility genes for prostate cancer identified by eQTL-based analyses. We find a significant overlap with 57 out of 104 previously reported genes assayed in our study also significant in TWAS. Third, we use a novel Bayesian prioritization approach to compute credible sets of genes and prioritize 120 genes that explain at least 90% of the posterior density for association signal at TWAS risk regions. One notable example, IRX4, had 97% posterior probability to explain the association signal at its region with the remaining 3% explained by 9 neighboring genes. Overall, our findings highlight the power of integrating gene expression data with GWAS and provide testable hypotheses for future functional validation of prostate cancer risk.
Results

Overview of methods
To identify genes associated with PrCa risk, we performed a TWAS using 48 gene expression panels measured in 45 tissues 22; 30-36 integrated with summary data from the OncoArray PrCa GWAS of 142,392 individuals of European ancestry (81,318/61,074 cases/controls; see Methods) 29 . We performed the summary-based TWAS approach as described in ref 25 using the FUSION software (see Methods). Briefly, this approach uses reference linkage-disequilibrium (LD) and reference gene expression panels with GWAS summary statistics to estimate the association between the cis-genetic component of gene expression, or alternative splicing events, and PrCa risk 25 ; see Table S1 ). Indeed, the number of gene models per panel was highly correlated with sample size, which implies that statistical power to detect genes with cis-regulatory control is limited by sample size (see Figure S1 ). Focusing only on models capturing total gene expression, genes on average had heritable levels of expression in 6.4 different panels (median 3) with 11,364 / 16,052 genes having heritable expression in at least 2 panels (see Figure 1 ). Predictive power of linear gene expression models is upperbounded by heritability; thus, we use a normalized ܴ ଶ to measure in-sample prediction accuracy
. We found the average ܴ ଶ / cis-݄ ଶ across all tissue-specific models was 61%, which indicates that most of the signal in cis-regulated total expression and alternative splicing levels is captured by the fitted models (see Figure 1 ). To assess the predictive stability for models of normal prostate gene expression, we compared measured and predicted gene expression for TCGA 36; 39 samples using models fitted in GTEx 22 normal prostate. We found a highly significant Figure S2 ), which is consistent with previous out-of-sample estimates 24; 25 . We performed a cross-tissue analysis within TCGA and found tumor prostate gene expression models replicated in normal prostate (total expression Table S2 ). Given the large number of genes having evidence of genetic control across multiple tissues, we next aimed to measure the similarity of different tissue models (see Methods). Across all reference panels for each gene we observed an average ܴ ଶ ൌ 0 . 6 4 (see Figure S3 ). Similarly, when averaging across genes, reference panels displayed an average cross-tissue ܴ ଶ ൌ 0 . 5 2 (see Figure S4 ). Together, these results suggest that trained models predict similar levels of cisregulated expression on average, despite reference panels measuring expression in different tissues, from varying QC, and capture technologies. Next, we performed simulations to measure the statistical power of TWAS under a variety of trait architectures (see Supplementary Note).
Consistent with previous work, we found TWAS to be well-powered at various effect-sizes and heritability levels for gene expression. Importantly, we found no inflation under the null when cisregulated gene expression has no effect on downstream trait (see Figure S5 ).
Multi-tissue TWAS identifies 235 genes associated with PrCa status
In total, we tested 117,459 tissue-specific gene models of expression for association with PrCa status and observed 932 reaching transcriptome-wide significance (ܲ ் ௐ ௌ ൏ 4 .
resulting in 235 unique genes, of which 118 were significant in more than one panel (see Table   S3 ; Figure 2 ). On average, we found 16.8 tissue-specific models associated with PrCa per reference expression panel (see Table S1 ). In 1Mb regions with at least 1 transcriptome-wide significant gene, we observed 10.7 tissue-specific associated models on average, and 2.7 associated genes on average, indicating that further refinement of association signal at TWAS risk loci is necessary. To quantify the overlap between non-HLA, autosomal risk loci in the OncoArray PrCa GWAS and our TWAS results, we partitioned GWAS summary data into 1Mb regions and observed 131 harboring at least one genome-wide significant SNP. Of these, 126/131 overlapped at least one gene model in our data and 68/131 overlapped at least one transcriptome-wide significant gene (see Figure S6 ). Associated genes were the closest gene to the top GWAS SNP 20% of the time when using 26,292 RefSeq genes. This result is consistent with previous reports 9; 25; 26 and suggests that prioritizing genes based on distance to index SNPs is suboptimal. We found gene model associations were largely consistent, further supporting the predictive stability of models using cis-SNPs (see Figure S7 ; Supplementary Note). We observed little evidence of prediction accuracy introducing biased results (see Figure   S8 ; Supplementary Note). As a partial control, we compared TWAS results with S-PrediXcan, a related method for predicting gene expression into GWAS summary statistics, using independently trained models and observed a strong correlation (ܴ ൌ 0 . 8 7 ; see Figure S9 ;
Supplementary Note), further supporting the validity of the TWAS approach.
Most of the gene models captured total expression levels in normal tissues, however as a positive control we included models for total expression in tumor prostate tissue (see Methods).
Predicted expression using tumor prostate models accounted only for 42/235 significant genes compared with 6/235 in normal prostate which is likely due to the large difference in sample size between the original reference panels (see Table S1 ). Given this, we found no significant increase in proportion of tumor prostate associated models compared with normal prostate (Fisher's exact
. Of the 335 genes with models trained in both reference panels a single shared gene, MLPH (OMIM: 606526, a gene whose function is related to melanosome transport 40 ), was associated with PrCa risk (see Table S2 ). 11/42 genes were significant only in tumor prostate models of total expression. 7/11 genes were modeled in other panels but did not reach transcriptome-wide significance while the other 4/11 were not significantly heritable, and thus not testable, in other panels. We also tested models of alternatively spliced introns for association to PrCa risk. We identified predicted expression of alternatively spliced introns in tumor prostate accounted for 69/235 genes, with an average of 2.5 (median 1) alternatively spliced intron associations per gene. We next quantified the amount of overlap between results driven from models of alternative splicing events versus models of total gene expression. 24/69 genes were found only in alternatively spliced introns, and 16/24 genes had models of total gene expression but did not reach transcriptome-wide significance. The remaining 8/24 were tested solely in alternatively spliced introns, due to heritability of total gene expression not reaching significance. Together these results emphasize earlier work demonstrating that sQTLs for a gene commonly capture signal independent of eQTLs 41 .
TWAS analysis increases power to find PrCa associations
Most of the power in the TWAS approach can be attributed to large GWAS sample size.
However, two other factors can increase power over GWAS. First, TWAS carries a reduced testing burden compared with that of GWAS, due to TWAS having many fewer genes compared with SNPs. 10/235 genes were located at 9 novel independent 1Mb regions (i.e. no overlapping GWAS SNP), all of which remained significant under a summary-based permutation test Table 1 ; Table S2 ; Methods). We found this result was stable to increasing region sizes (see Table S4 ) and unlikely be the result of long-range tagging with known GWAS risk (see Table S5 ; Supplemental Note). We observed increased association signal for SNPs at these regions compared to the genome-wide background after accounting for similar MAF and LD patterns (see Figure S10 ), which, together with observed TWAS associations, suggests that GWAS sample size is still a limiting factor in identifying PrCa risk SNPs. As a partially independent check, we performed a multi-tissue TWAS using summary data from an earlier PrCa GWAS (ܰ ൌ 4 9 , 3 4 6 ) 7 and found 2 novel regions. We found both regions to overlap a genome-wide significant SNP within 1Mb in this data further supporting the robustness of TWAS (see Table S6 ). Second, we expect to observe increased association signal when expression of a risk gene is regulated by multiple local SNPs 25 
TWAS replicates previously reported genes
We next sought to quantify the extent of overlapping results between TWAS and previous studies that integrated eQTL data measured in normal and tumor prostate tissues at PrCa risk regions (see Methods; see Table S7 ) 5; 14-20 . We considered only autosomal, non-HLA genes which resulted in 130 previously reported genes. We found a significant overlap between reported genes, with 104/130 assayed in our study and 57/104 reaching transcriptome-wide significance in at least one of our panels (Fisher's exact Tables S7-S8 ).
For example, MLPH was reported in 4/8 studies. We found significant associations suggesting that decreased expression of MLPH in normal and tumor prostate tissue increases risk for PrCa (e.g., GTEx prostate MLPH
Predicted MLPH in tumor prostate remained significant under permutation, which suggests that chance co-localization with GWAS risk is unlikely (Table S2 ).
To assess the amount of residual association signal due to genetic variation in the GWAS risk region after accounting for predicted expression of MLPH we performed a summary-based conditional analysis (see Methods). We found MLPH to explain most of the signal at its region Figure 3 ). Our findings are consistent with recent work that found decreased expression levels of MLPH to be associated with increased PrCa risk 45 . Despite previous eQTL data focusing on normal and tumor prostate tissue, we observed associations in 49 expression panels overlapping the 57 observed genes in total, underscoring earlier works demonstrating the consistency of cross-tissue cis-regulatory effects 46 .
Bayesian prioritization pinpoints a single gene for most TWAS risk regions
TWAS genes are indicative of association and do not necessarily reflect causality (e.g., due to co-regulation at the same region). To prioritize genes at regions with multiple TWAS signals ( Figure 2 ), we used a Bayesian formulation to estimate 90%-credible gene sets (see Methods).
We found 120 unique genes across 87 non-overlapping 1Mb regions comprising our 90% credible sets (see Tables S9-S10). 71/87 credible sets contained either a single gene or the same gene in multiple tissues. The average number of unique genes per credible set was 1.38 (median 1). 27/120 prioritized genes were previously reported in eQTL analyses 5; 14-20 , which supports the hypothesis that TWAS followed by Bayesian prioritization refines associations to relevant disease genes. For example, MLPH was the sole gene defining its region's 90% credible set with a posterior probability of 94%. Similarly, SLC22A3 (OMIM: 604842; a gene involved in polyspecific organic cation transporters 47 and previously implicated in PrCa risk 18 ) exhibited > 94% posterior probability to be causal.
Expression and splicing events predicted in prostate tissue have largest average effect
Given the large number of significant associations observed for non-prostate tissues in our data, we wanted to quantify which tissue is most relevant for PrCa risk. We first grouped TWAS PrCa associations into prostate/non-prostate and tested for enrichment in normal and tumor prostate expression models. Predicted expression and splicing events in normal and tumor prostate made up 223/932 associations with PrCa (see Table S2 ) which was highly significant compared to the grouping of all other tissues (Fisher's exact
. This measure only quantifies the total amount of observed associations and neglects average association strength. Next, we computed the mean TWAS association statistic using all genes predicted from each expression reference panel (see Figure 4 ). We observed the largest average TWAS associations in genes predicted from normal and tumor prostate tissue, which reaffirms our intuition of expression and slice events in prostate being the most relevant for PrCa risk. We re-ranked mean associations using only genes found to be transcriptome-wide significant and observed a similar ordering with total expression in normal prostate ranked highest (average ߯ ଶ ൌ 1 7 6 . 2 ; see Figure S11 ).
Discussion
Prostate cancer is a common male cancer that is expected to affect more than 180,000 men in the United States in 2017 alone 48 . While GWAS has been successful in localizing risk for PrCa due to genetic variation, the underlying susceptibility genes remain elusive. Here, we have presented results of a transcriptome-wide association study using the OncoArray PrCa GWAS summary statistics for over 142,000 case/control samples. This approach utilizes imputed expression levels and splicing events in the GWAS samples to identify and prioritize putative susceptibility genes. We identified 235 genes whose expression is associated with PrCa risk.
These genes localized at 87 genomic regions, of which 9 regions do not overlap with a genomewide significant SNP in the OncoArray GWAS. We found 24 genes using predictive models for alternatively spliced introns in tumor prostate, which supports the its role in continued risk for tumor oncogenesis. A large fraction of identified genes was confirmed in earlier work, with 57 genes previously reported in eQTL/PrCa GWAS overlap studies. We used a novel Bayesian prioritization approach to refine our associations to credible sets of 120 genes with statistical evidence of causality under standard assumptions. Our results provide a functional map for PrCa risk which can be explored for follow-up and validation.
In this study, we compared our reported TWAS results with genes identified in previous works focusing on expression measured in normal and tumor prostate tissue. Several of these studies .
Thus, our inability to detect heritable levels of gene expression can be explained due to the relatively small number of samples compared with other tissues. Indeed, previous work has shown a strong correlation between sample size in expression panels and the number of identified eGenes 27 ; therefore, as sample size increases for relevant tissues, we expect the number of genes included in the TWAS framework to increase. TWAS will lose power in situations where gene expression is a non-linear function of local SNPs, or when trans (or distal) regulation is a major component in modulating expression levels.
We conclude with several caveats and possible future directions. First, while TWAS associations are consistent with models of steady-state gene expression levels altering risk for PrCa, they may be the result of confounding 25 We thank the following for funding support: 
Methods
OncoArray GWAS summary statistics
Genome-wide association summary statistics for the OncoArray PrCa study were obtained from ref 29 
Previous studies investigating the overlap of eQTL in prostate with risk of PrCa
We collected previous studies that investigated the overlap of eQTLs in normal and tumor prostate tissue at known PrCa risk loci 5; 14-20 . We compared TWAS statistics versus reported eQTL overlap results as aggregated in refs 14; 15 . Across these studies, overlap of eQTLs and PrCa risk loci are computed by one of two possible methods. The first method tests known PrCa risk SNPs for association with expression levels of nearby genes/transcripts. The second method takes a two-step approach. First, genes nearby PrCa risk loci are tested for harboring eQTLs at some significance level. Next, genes with identified eQTL SNPs are tested to be in LD with known PrCa risk variants at some level (e.g.,
).
Reference gene expression data sets and predictive models of expression
We downloaded the FUSION software (see URLs) along with its prepackaged weights for gene expression data. FUSION is an R package that implements the TWAS scheme described in ref 25 . Weights for gene expression measured using RNA sequencing data were obtained from the CommonMind Consortium 30 ). All non-TCGA expression panel individuals were PrCa controls. Detailed description of quality control procedures on measured gene expression and genotype information for all non-TCGA reference panels are described in refs 25; 27 . TCGA genotype, gene expression, and exon-junction data for 525 samples were downloaded using the Broad GDAC FireHose version 2016_1_28 (see URLs). Genotypes were imputed to the Haplotype Reference Consortium 51 and restricted to well-imputed (INFO > 0.9) HapMap3 52 sites. Genes (exon junctions) missing in more than half of samples were removed. RPKM and log-adjusted gene expression levels were estimated in a generalized linear model controlling for 3 gene-expression PCs and ranknormalized. We estimated alternatively spliced introns using the software MapSplice version 2 (see URLs). A total of 482 samples passed quality control procedures in both genotype and gene expression data.
We filtered genes that did not exhibit cis-genetic regulation at current samples sizes by keeping only genes with nominally significant (ܲ 
Cis-heritability of gene expression
Measuring cross-tissue similarity in predicted expression
We took an unbiased approach to identify susceptibility genes for PrCa by using gene expression panels measured in various tissues. To quantify how similar predicted expression levels are for the same gene across different tissues we measured the squared Pearson correlation (ܴ ଶ ). This value represents how well predicted expression from one tissue may be used to predict expression in another tissue. To dissect similarities and differences of tissuespecific models, the ideal scenario would be to inspect effects at individual SNPs defining the models. In practice this is not possible due to predictive models not including the same set of SNPs due to QC and technological differences in the original studies. Therefore, as a proxy we predict gene expression into the 489 samples of European ancestry from 1000 Genomes 53 and compute ܴ ଶ across shared genes for pairs of tissues (see Supplementary Note) . 
Transcriptome-wide association study using GWAS summary statistics
where is a correlation matrix across SNPs at the locus (i.e. LD) and "'" indicates transpose. A is the number of predictive models. As reported by ref 25 , there may be inflation at GWAS risk loci, due to chance co-varying of SNP effects between expression and PrCa. The same work described a permutation procedure that assesses likelihood of observing association by chance conditioned on GWAS signal. The algorithm works by permuting the eQTL weights Table S4 ).
GWAS analyses conditional on predicted expression
To assess the extent of residual association of SNP with PrCa risk after accounting for predicted gene expression levels, FUSION estimates conditional SNP association scores using GWAS summary statistics. Namely, define as LD for SNPs in the region, as the correlation between predicted expression levels, and as the correlation between SNPs and predicted expression. The least-squares estimates of
The variance of the residual association strength is given by,
This results in the final conditional association score for the ݅ th SNP as,
.
Bayes factors and posterior inference of causal genes
Complex correlations between predicted expression levels at a given region can yield multiple associated genes in TWAS (see Figure 2 
Pathway analyses
To determine which pathways may be enriched with genes identified from our Bayesian prioritization approach, we used the R package GOseq 57 which internally links gene identifiers to GO terms (GO db: 2017-09-02). We categorized all 17,023 genes into prioritized/notprioritized and ran the analysis using custom R scripts linking GOseq. GOseq obtains P-values for overrepresented genes using the Wallenius approximation to the non-central hypergeometric distribution. We limited analysis to Gene Ontology Biological Pathways (GO:BP). GOSeq drops genes without GO categories from analysis. We observed 5,005 genes dropped from analyses resulting in 12,018 genes put forward for enrichment tests (see Table S10 ; Supplementary Note).
Tables Table 1. Novel risk loci. TWAS associations that did not overlap a genome-wide significant SNP (i.e. ± 1Mb transcription start site). Study denotes the original expression panel used to fit weights. P-value for TWAS computed under the null of no association between gene expression levels and PrCa risk under a Normal(0, 1) distribution. An asterisk (*) indicates associations that are nominally significant (ܲ 
